An interventional study of long-term high-risk drinking and non-drinking in Sedation, sponsored by Affiliated Hospital of Jiaxing University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Affiliated Hospital of Jiaxing University · Not applicable, Interventional, and Treatment
this study aims to investigate the effect of chronic high-risk alcohol consumption on the effective dose of oliceridine combined with propofol for painless gastroscopy, so as to provide a reference for rational clinical medication.
The primary objective of our study is to use a biased coin up-down alloocation methology to estimate the dose of oliceridine combined with propofol for sedation of painless gastroscopy. Thus, this study was designed to compare the effective doses of oliceridine for successful insertion of gastroscopy between long-term high-risk drinking and non-drinking patients.
Affiliated Hospital of Jiaxing University is the lead sponsor of 17 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exclusion of cases: prolonged examination time due to difficult endoscopic manipulation; severe complications requiring emergency treatment such as hypoxemia and circulatory fluctuation, which violate the study protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First patient's use of Osselidin and next patient's use of Osselidin
Other: long-term high-risk drinking
First patient's use of Osselidin and next patient's use of Osselidin
Other: non-drinking
If a patient had failed gastroscope insertion, the next patient would receive a higher dose (an increasing of 1.5 μg/kg). However, if a patient had successful gastroscpe insertion, the next patient would receive a lower dose (a decreasing of 1.5 μg/kg) with a probability of approximately B ≈ 0.11 (i.e., 1/9), or the same dose with a probability of 1 - B = 0.89 (i.e., 8/9). The initial dosage of oliceridine was set at 13 μg/kg, with an up-down dose of 1.5 μg/kg, based on our hospital's experience and findings in the literature.
If a patient had failed gastroscope insertion, the next patient would receive a higher dose (an increasing of 1.5 μg/kg). However, if a patient had successful gastroscpe insertion, the next patient would receive a lower dose (a decreasing of 1.5 μg/kg) with a probability of approximately B ≈ 0.11 (i.e., 1/9), or the same dose with a probability of 1 - B = 0.89 (i.e., 8/9). The initial dosage of oliceridine was set at 13 μg/kg, with an up-down dose of 1.5 μg/kg, based on our hospital's experience and findings in the literature.
ED₉₀ of the two groups
the effective doses of oliceridine for successful insertion of gastroscopy between long-term high-risk drinking and non-drinking patients.
Time frame: 30 minutes
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Affiliated Hospital of Jiaxing University